Israeli biotech Polyrizon announced that it is beginning preclinical development of an intranasal naloxone formulation based on the company’s Trap and Target mucoadhesive technology. The company said that Fabio Sonvico of the University of Parma, who is a member of Polyrizon’s scientific advisory board, will conduct the studies.
Polyrizon CEO Tomer Izraeli commented, “The opioid crisis continues to be a global public health emergency and improving naloxone administration is essential for saving lives. Our proprietary T&T platform is designed to optimize drug delivery, and we believe it holds the potential to enhance intranasal naloxone by offering higher bioavailability for increased drug effectiveness and optimized drug release profiles that ensure rapid opioid reversal when every second counts. These advantages could make a critical difference in emergency overdose situations, providing a safer and more accessible solution for at-risk individuals and first responders.”
The company also has announced that it has signed a letter of intent with an undisclosed company that specializes in psychedelic therapies. Under the agreement, the other company will fund development of an intranasal formulation of an undisclosed psychedelic using Polyrizon’s nasal hydrogel technology. According to the announcement, the letter of intent is non-binding but the companies plan to enter into a definitive agreement if feasibility studies are successful.
Polyrizon has already been partnered on nasal formulation projects with SciSparc and NurExone for several years. In October 2024, the company announced that it had closed a $4.2 million IPO to fund continued development of its intranasal platforms.
Read the Polyrizon press release on intranasal naloxone
Read the Polyrizon press release on the letter of intent
